Marksans Pharma is currently trading at Rs. 22.95, up by 0.25 points or 1.10% from its previous closing of Rs. 22.70 on the BSE.
The scrip opened at Rs. 23.00 and has touched a high and low of Rs. 23.60 and Rs. 22.80 respectively. So far 41707 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 40.55 on 04-Sep-2018 and a 52 week low of Rs. 20.95 on 14-May-2019.
Last one week high and low of the scrip stood at Rs. 23.60 and Rs. 21.65 respectively. The current market cap of the company is Rs. 929.14 crore.
The promoters holding in the company stood at 48.25%, while Institutions and Non-Institutions held 4.07% and 47.68% respectively.
Marksans Pharma has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Goa facility. The inspection at the company's facility was carried out from February 25 to March 06, 2019.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: